Tag:

Emergent BioSolutions

Latest Headlines

Latest Headlines

Emergent BioSolutions expanding with $222M deal to buy Cangene

Emergent BioSolutions, already the go-to company for anthrax vaccines, will buy Cangene Corp. for about $222 million, adding to its stable of biodefense contracts and picking up a contract manufacturing business that can kick in some additional revenue.

FDA lifts clinical hold on anthrax vaccine

The FDA has lifted the clinical hold on PharmAthene's anthrax vaccine candidate, SparVax.

Emergent, VaxInnate sign pandemic flu vaccine deal

Emergent BioSolutions snagged the exclusive right to manufacture and sell VaxInnate's flu vaccine, a product Emergent can produce quickly at high yields and low cost.

TB vaccine tested in infants of HIV-positive mothers

University of Cape Town's South African Tuberculosis Vaccine Initiative and Stellenbosch's Desmond Tutu TB Centre are recruiting infants to test a new tuberculosis vaccine for newborns of HIV-positive moms, a demographic not served by the current vaccine.

Targacept taps Stephen A. Hill to serve as president and CEO

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Novartis, Emergent headline $400M HHS plan to combat health threats

Several biopharma players--including Emergent Biosolutions, GlaxoSmithKline and Novartis--landed on the winning end of contracts from the U.S. Department of Health and Human Services to develop and churn out treatments against bioterror and pandemic threats. To fund the first phase of the effort, the HHS has committed $400 million.

Abbott nixes cancer drug alliance with Emergent BioSolutions

Emergent BioSolutions ($EBS) has suffered a setback in its campaign to expand into cancer drug development. Abbott Labs ($ABT) has decided to dump a partnership with Emergent on the development of

Emergent BioSolutions gets gov't order for BioThrax

Emergent BioSolutions could earn up to $1.25 billion over the next 5 years for providing 44.8 million doses of its BioThrax anthrax vaccine to the U.S. government. The developer revealed in May the

Aeras kicks off TB trial in HIV patients

In an effort to combat tuberculosis, Aeras and the Oxford-Emergent Tuberculosis Consortium have announced the start of a Phase IIb trial of the MVA85A vaccine. The 1,400-person proof-of-concept study

U.S. increases Emergent BioSolutions' anthrax vax contract

Emergent BioSolutions is adding another 3.42 million doses to its 14.5 million-dose BioThrax contract with the U.S. government. The contract extension is worth an approximate $101 million; the